drugset

drugset / Trial / NCT04816721

A Study to Evaluate EDP 938 Regimens in Children With RSV

NCT04816721 ↗

Phase 2 Completed 99 enrolled Enanta Pharmaceuticals, Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

Timeline

Start: 2022-04-26
Primary completion: 2024-08-19
Completion: 2024-08-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	zelicapavir	Small molecule	—	Oral

Indications